The global pharmaceutical landscape is currently undergoing a period of profound transformation, characterized by the rapid emergence of complex biologics, the push for decentralized manufacturing, and an increasingly stringent regulatory environment. To navigate these shifts, the American Association of Pharmaceutical Scientists (AAPS) and the United States Pharmacopeia (USP) have announced a major expansion of their collaborative efforts for the upcoming PharmSci 360 conference, set to take place October 25–28, 2026, at the Ernest N. Morial Convention Center in New Orleans.
This year’s partnership represents a strategic evolution in the relationship between these two industry pillars. While USP has long maintained a presence at PharmSci 360, this year’s engagement transcends the traditional exhibition model, introducing a comprehensive, two-and-a-half-day dedicated workshop that promises to bridge the gap between academic research, industrial application, and regulatory enforcement.
The Core Agenda: Bridging Standards and Innovation
At the heart of the 2026 conference is a concerted effort to align scientific innovation with the rigorous standards required to ensure patient safety. The centerpiece of the USP’s involvement is a workshop running from October 26 to 28, situated directly within the exhibit hall. This initiative is designed to provide attendees with a deep dive into the technical nuances of the USP–NF (United States Pharmacopeia–National Formulary).
These compendial standards serve as the bedrock of pharmaceutical quality in the United States, providing the public specifications that the FDA enforces under the Federal Food, Drug, and Cosmetic Act. The 2026 workshop will specifically tackle four critical pillars of modern drug development:
- Complex Generics: As the patent cliff approaches for many blockbusters, the industry is pivoting toward more complex generic formulations. The workshop will examine how to maintain rigorous quality standards while accelerating the development of these challenging products.
- Excipient Quality: Often considered the “silent partners” in drug delivery, excipients are receiving increased scrutiny. The sessions will focus on the interplay between raw material quality and the final performance of drug products.
- Inhalation Standards: Given the complexity of pulmonary drug delivery, the industry faces unique analytical challenges. The workshop will provide guidance on ensuring consistency in inhalation-based therapies.
- Novel Excipients: As drug delivery systems become more sophisticated, the need for new, functional excipients is growing. The workshop will explore the path to regulatory acceptance for these novel materials.
By embedding these topics within the exhibit hall, the organizers aim to foster a dynamic environment where researchers, manufacturers, and policy experts can engage in real-time problem solving.
A Chronology of Collaboration: From Booths to Workshops
The trajectory of the AAPS-USP partnership reflects the changing needs of the industry. Historically, USP’s presence at major conferences was largely informational. In 2023, the focus was centered on a targeted discussion regarding excipient and raw material grades—a vital topic, but one that only scratched the surface of the growing demand for technical guidance.
By 2025, the collaboration matured, with USP hosting exhibit-hall stage sessions that allowed for broader audience engagement. The decision to expand to a two-and-a-half-day workshop in 2026 signals a recognition that modern drug development challenges—such as the transition to continuous manufacturing and the rise of personalized medicine—cannot be addressed in short, siloed presentations.
The 2026 event will also feature a dedicated poster collection and a permanent presence at booth 2931, ensuring that attendees have continuous access to USP experts throughout the four-day conference.
Deep Integration: The Scientific Program
Beyond the dedicated workshop, USP staff members are deeply embedded in the primary scientific program for PharmSci 360. This reflects a strategic move to ensure that “quality by design” principles are baked into the early stages of drug discovery.
Biologics and the $10-per-gram Goal
One of the most anticipated sessions features Diane McCarthy, Ph.D., VP of global biologics at USP, who will address the future of public standards for biologics development. This symposium, moderated by Allison Radwick, Ph.D., explores the provocative question posed by Anurag Rathore (Indian Institute of Technology Delhi): Can next-generation platforms actually produce monoclonal antibodies at a cost of $10 per gram?
This discussion is critical to the future of global health equity. By lowering the manufacturing barrier for biologics, the industry could theoretically make life-saving therapies accessible to a much larger patient population. The panel will also feature insights from AbbVie’s Tongzhou Liu on formulation choices in commercial manufacturing, and Moderna’s Luis Brito, who will provide a high-level overview of the lipid nanoparticle (LNP) landscape—a technology that gained global prominence during the mRNA vaccine rollout and continues to be a focal point for delivery science.
Predictive Development and Scalability
The conference will also feature two keynotes moderated by Ravi Kiran Kaja, Ph.D., a senior principal scientist at USP. These sessions highlight the industry’s shift toward predictive modeling and advanced scaling techniques. Alan Watts (Catalent) is slated to discuss the scale-up of the Parkinson’s treatment Inbrija, providing a masterclass in translating complex inhalation formulations from the lab to the commercial manufacturing floor. Complementing this, Shawn Zhang (digiM Solution) will discuss the role of microstructure-based predictive development, emphasizing how digital twins and computational modeling are replacing traditional "trial-and-error" approaches to formulation.
Official Perspectives: Aligning Missions
The collaboration is rooted in a shared philosophy regarding the role of standards in an era of rapid technological advancement. Catherine Sheehan, senior director of growth programs for excipients and foods at USP, noted the importance of this alignment in a recent statement.
“USP and AAPS are aligned in our shared mission to help industry and regulators address evolving challenges in pharmaceutical quality,” Sheehan stated. “This workshop will bring together a range of stakeholder perspectives to foster innovation, strengthen regulatory confidence, and ultimately help increase the availability of quality medicines for the patients who need them.”
For the AAPS, the partnership provides a platform to offer members practical, actionable advice on how to navigate the complex regulatory pathway. For the USP, the collaboration provides a vital feedback loop; by listening to the challenges faced by the AAPS membership, the USP can better understand where to update or create new compendial standards that support, rather than hinder, innovation.
The Broader Implications: Why This Matters
The PharmSci 360 conference in 2026 is poised to be a barometer for the health of the pharmaceutical industry. The shift toward more complex, individualized, and high-tech therapies creates a unique "quality gap." When processes move too fast, or when new technologies like AI-driven drug discovery outpace the development of standardized analytical methods, the result is often regulatory uncertainty and supply chain fragility.
Regulatory Confidence
By bringing regulators and industry leaders together, the USP-AAPS workshop aims to build "regulatory confidence." If companies can demonstrate that they are following, or contributing to, globally recognized standards, the path to FDA approval becomes significantly smoother. This is particularly relevant for the growing field of advanced therapies, where standardized manufacturing processes are still being defined.
Supply Chain Resilience
The emphasis on raw materials and excipient quality is not merely a technical concern; it is a matter of national security and supply chain integrity. The COVID-19 pandemic highlighted the fragility of the pharmaceutical supply chain. By fostering a deeper understanding of quality specifications at the raw material level, the industry is better positioned to diversify its supply chains and ensure that the final drug products reaching patients are both safe and effective.
Democratizing Innovation
The focus on cost-efficient manufacturing for biologics, as highlighted in the symposium sessions, suggests a maturing industry. The "high-cost, high-reward" model of the past is being challenged by a need for sustainability and volume. The insights shared at PharmSci 360 will be instrumental for startups and established giants alike as they look for ways to optimize their manufacturing footprints.
Conclusion: A Must-Attend Event
As the pharmaceutical industry moves into the latter half of the decade, the ability to synthesize scientific research with regulatory reality will be the defining trait of successful organizations. The 2026 PharmSci 360 conference, through its deepened partnership with the USP, offers a unique opportunity to engage with these critical issues.
Whether focusing on preclinical, clinical, or translational sciences; formulation and delivery; or advanced manufacturing and analytical characterization, the conference program is designed to cover the entire development pipeline. With the added weight of the USP workshop, this year’s PharmSci 360 is not just a meeting for scientists—it is a strategic summit for the future of medicine.
For those planning to attend, the program is already accessible through the official AAPS portal. As the industry looks toward New Orleans in October 2026, the message is clear: the path to innovation is paved with quality, and the bridge to that quality is built through collaboration.
About the Author
